Concord Biotech Limited vs Wockhardt Limited

Last updated: 21 October 2026

In the dynamic landscape of the Indian pharmaceutical sector, investors often seek opportunities across a spectrum of companies, from established players to emerging specialists. Today, we put two intriguing entities under the microscope: Concord Biotech Limited (CONCORDBIO.NS) and Wockhardt Limited (WOCKPHARMA.NS). Both operate within the broad pharmaceutical industry, albeit with different focuses and market positions. Concord Biotech is known for its biopharmaceutical products, particularly fermentation-based APIs, while Wockhardt is a global pharmaceutical and biotechnology organization with a diverse product portfolio. We compare them to help investors understand their current standing based on key financial metrics.

Key Financial Metrics Comparison

Metric	Concord Biotech Limited	Wockhardt Limited
Current Price	₹1270.00	₹1877.20
52W High	₹1579.40	₹2329.70
52W Low	₹1014.80	₹1100.30
1-Year Return	-6.66%	39.99%
Trailing P/E	N/A	N/A
Market Cap	N/A	N/A

Analysis: Valuation, Returns, and Stability

Valuation: Unfortunately, a direct comparison based on valuation metrics like Trailing P/E and Market Cap is not possible at this time as the data for both Concord Biotech and Wockhardt is listed as 'N/A'. This limitation prevents a clear assessment of which stock might be more 'expensive' or 'cheaper' relative to its earnings or overall size. Investors would need to seek additional fundamental data to make a valuation-based decision.

Returns: On the returns front, Wockhardt Limited clearly outperforms Concord Biotech Limited. Wockhardt has delivered a robust 1-Year Return of 39.99%, indicating strong positive momentum over the past year. In contrast, Concord Biotech has seen a negative 1-Year Return of -6.66%. This suggests that Wockhardt has been a more rewarding investment in the short to medium term for shareholders.

Stability: To assess stability, we look at the 52-Week High and Low relative to the Current Price. Concord Biotech's current price of ₹1270.00 is closer to its 52-Week Low of ₹1014.80 than its 52-Week High of ₹1579.40, indicating it has fallen significantly from its peak. Wockhardt, with a current price of ₹1877.20, is also off its 52-Week High of ₹2329.70 but has shown stronger upward momentum as evidenced by its positive 1-year return. The range between high and low for Wockhardt (₹1100.30 to ₹2329.70) is wider than that of Concord Biotech (₹1014.80 to ₹1579.40), suggesting Wockhardt might experience greater volatility. However, its strong positive return indicates this volatility has largely been on the upside.

MoneyDock Verdict

For Aggressive Investors: Wockhardt Limited (WOCKPHARMA.NS) appears more attractive due to its strong 1-Year Return of 39.99%. While it might exhibit higher volatility, the recent performance indicates significant upside potential, aligning with an aggressive investment strategy seeking higher gains.

For Conservative Investors: Given the current data, neither stock presents a clear 'conservative' choice, especially with the absence of P/E ratios and market caps. However, Concord Biotech's negative 1-year return and position closer to its 52-week low might suggest it's in a consolidation phase or facing headwinds, which typically carries more risk for conservative portfolios. More information is needed for a truly conservative assessment.

For Long-Term SIP Investors: Without P/E ratios and market capitalization, making a definitive long-term SIP recommendation is challenging. However, Wockhardt's positive momentum and higher current price suggest it has been in an uptrend, which can be beneficial for SIP if the trend continues. Concord Biotech, with its negative return, would require deeper fundamental analysis to determine if it offers a compelling long-term value at its current price, especially if one believes in a turnaround.

Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.